{"id":128003,"date":"2019-11-15T11:55:50","date_gmt":"2020-04-21T02:29:58","guid":{"rendered":"http:\/\/www.05921.net\/index.php\/128003\/"},"modified":"2020-04-21T10:30:01","modified_gmt":"2020-04-21T02:30:01","slug":"35a54edf5a","status":"publish","type":"post","link":"https:\/\/www.05921.net\/index.php\/128003\/","title":{"rendered":"\u4e00\u62db\u89e3\u51b3\u300c\u4e03\u5e74\u4e4b\u75d2\u300d\uff01\u7279\u5e94\u6027\u76ae\u708e\u836f\u7269 Dupilumab \u6b65\u5165\u4e2d\u56fd\uff0c\u6df1\u5ea6\u89e3\u8bfb\u6cbb\u7597\u4e2d\u91cd\u5ea6\u300c\u96be\u5fcd\u4e4b\u75d2\u300d\u7684\u5168\u65b0\u5229\u5668"},"content":{"rendered":"
\n
\n
\n

\u670b\u53cb\uff0c\u4f60\u542c\u8bf4\u8fc7 AD \u5417\uff1f<\/span><\/p>\n


<\/p>\n

<\/section>\n

\u4e0d\u4e0d\uff0c\u4e0d\u662f\u8bf4\u963f\u5c14\u8328\u6d77\u9ed8\u75c5\uff0c\u4f46\u8fd9\u4e2a AD\uff0c\u8bba\u53ef\u6015\u7a0b\u5ea6\u5374\u6beb\u4e0d\u900a\u8272\uff0c\u5b83\u53eb\u7279\u5e94\u6027\u76ae\u708e\uff08Atopic Dermatitis\uff09\u3002<\/strong><\/span><\/p>\n


<\/p>\n

<\/section>\n

\u7619\u75d2\u96be\u5fcd\u5230\u65e0\u6cd5\u5165\u7761\u3001\u76ae\u80a4\u635f\u4f24\u5230\u591c\u4e0d\u80fd\u5bd0\uff0c\u5916\u52a0\u5404\u79cd\u4f34\u968f\u75c7\u72b6\u7684\u6298\u78e8\u2026\u2026\u60f3\u50cf\u4e00\u4e0b\u5c31\u591f\u53d7\u4e86\u3002<\/span><\/strong>\u7136\u800c\u5bf9\u8fd9\u79cd\u5f71\u54cd\u7740\u5168\u7403\u6570\u4ee5\u4ebf\u8ba1\u60a3\u8005\u7684 AD\uff0c\u6050\u6015\u4e0d\u5c11\u4eba\u4e00\u65e0\u6240\u77e5\uff0c\u66f4\u4e0d\u77e5\u9053\u6297\u51fb\u5b83\u7684\u65b0\u5229\u5668\u5427\uff1f<\/span><\/p>\n


<\/p>\n

\"\u4e00\u62db\u89e3\u51b3\u300c\u4e03\u5e74\u4e4b\u75d2\u300d\uff01\u7279\u5e94\u6027\u76ae\u708e\u836f\u7269<\/p>\n

\u56fe\u7247\u6765\u6e90\uff1a\u7ad9\u9177\u6d77\u6d1b<\/span><\/p>\n


<\/p>\n

<\/section>\n

\u5728\u8fd1\u671f\u7684\u7b2c\u4e8c\u5c4a\u4e2d\u56fd\u56fd\u9645\u8fdb\u53e3\u535a\u89c8\u4f1a\u4e0a\uff0c\u4e00\u6b3e\u540d\u53eb Dupilumab \u7684\u836f\u7269\u5728\u4e2d\u56fd\u9996\u6b21\u7ad9\u5230\u4e86\u524d\u53f0\u3002\u4ec0\u4e48\uff0c\u4f60\u95ee\u5b83\u5565\u6765\u5934\uff1f\u4e13\u514b\u8fd9\u79cd AD \u7684\u300c\u91cd\u78c5\u70b8\u5f39\u300d\uff0c\u542c\u8fc7\u6ca1\u6709\uff1f<\/span><\/p>\n


<\/section>\n

<\/section>\n
<\/section>\n

AD \u60a3\u8005\u5c11\uff1f<\/span><\/strong><\/span><\/strong>\u53ef\u80fd\u53ea\u662f\u4f60\u4e0d\u77e5\u9053<\/span><\/strong><\/span><\/strong><\/span><\/p>\n


<\/p>\n

\u80fd\u7b26\u5408\u300c\u5168\u7403\u8303\u56f4\u5185\u5e7f\u6cdb\u6d41\u884c\u300d\u6807\u51c6\u7684\u6162\u6027\u75be\u75c5\u5e76\u4e0d\u591a\uff0c\u7279\u5e94\u6027\u76ae\u708e\u5c31\u7edd\u5bf9\u7b97\u5f97\u4e0a\u4e00\u4e2a\u3002<\/span>\u6574\u4f53\u6765<\/span>\u770b\uff0c\u7279\u5e94\u6027\u76ae\u708e\u7684\u60a3\u8005\u5728\u6210\u5e74\u4eba\u4e2d\u6709 5-10%\uff0c\u513f\u7ae5\u4e2d\u66f4\u8fbe\u5230 10-15%<\/span>[1]<\/sup>\u3002<\/span><\/span><\/strong>\u8fd9\u4e9b\u6bd4\u4f8b\uff0c\u4e58\u4ee5\u4e2d\u56fd\u7684\u5e9e\u5927\u4eba\u53e3\u6570\u91cf\uff0c\u5c31\u610f\u5473\u7740\u6570\u4ee5\u5343\u4e07\u8ba1\u7684\u60a3\u8005\u3002<\/span><\/p>\n


<\/section>\n

\u76ee\u524d\u4e2d\u56fd\u7279\u5e94\u6027\u76ae\u708e\u60a3\u8005\u7684\u6570\u636e\u5e76\u4e0d\u591a\uff0c\u4f46\u51e0\u6b21\u5bf9\u513f\u7ae5\u7684\u8c03\u67e5\u5374\u663e\u793a\uff0c\u513f\u7ae5\u7684\u7279\u5e94\u6027\u76ae\u708e\u60a3\u75c5\u7387\uff0c\u5df2\u7ecf\u4ece 2002 \u5e74\u7684\u5927\u7ea6 3% \u5feb\u901f\u4e0a\u5347\u5230\u4e86 2016 \u5e74\u7684\u8fd1 13%<\/span>[2]<\/sup>\uff0c<\/span>\u7b97\u4e0a\u6210\u5e74\u60a3\u8005\uff0c\u90a3\u5728\u76ae\u80a4\u79d1\u7684\u95e8\u8bca\u60a3\u8005\u4e2d\uff0c\u6709\u5dee\u4e0d\u591a 8% \u88ab\u786e\u8bca\u4e3a\u7279\u5e94\u6027\u76ae\u708e <\/span>[3]<\/sup>\u3002<\/span><\/strong><\/span><\/p>\n


<\/section>\n

\u8fd9\u4e2a\u6bd4\u4f8b\u53ef\u80fd\u8fd8\u662f\u4f4e\u4f30<\/span><\/strong>\uff0c\u56e0\u4e3a\u7279\u5e94\u6027\u76ae\u708e\u7684\u8868\u73b0\u591a\u79cd\u591a\u6837\uff0c\u4e00\u4e9b\u60a3\u8005\u53ef\u80fd\u56e0\u4e3a\u75c7\u72b6\u4e0d\u5178\u578b\u88ab\u6f0f\u8bca\uff0c\u6216\u8005\u60a3\u8005\u81ea\u5df1\u4e5f\u628a\u7279\u5e94\u6027\u76ae\u708e\u4e0e\u6e7f\u75b9\u4e4b\u7c7b\u7684\u75be\u75c5\u6df7\u6dc6\u3002\u6240\u4ee5\u8bf4\uff0c\u7279\u5e94\u6027\u76ae\u708e\u79bb\u6211\u4eec\u771f\u7684\u4e00\u70b9\u513f\u90fd\u4e0d\u8fdc\u3002<\/span><\/p>\n


<\/section>\n

\u4e0d\u81f4\u547d\u4f46\u8981\u547d\uff0c\u4e3a\u4ec0\u4e48\u8fd9\u4e48\u8bf4\u5462\uff1f<\/span><\/p>\n


<\/section>\n

\u770b\u770b\u7279\u5e94\u6027\u76ae\u708e\u7684 Williams \u8bca\u65ad\u6807\u51c6\u5c31\u77e5\u9053\u4e86\uff0c\u6301\u7eed\u8db3\u8db3 12 \u4e2a\u6708\u7684\u76ae\u80a4\u7619\u75d2\uff0c\u7adf\u7136\u8fd8\u53ea\u662f\u524d\u63d0\uff01<\/span><\/strong>\u7619\u75d2\u5f80\u5f80\u8fd8\u4f34\u968f\u7740\u76ae\u80a4\u635f\u4f24\uff0c\u751a\u81f3\u53ef\u80fd\u662f\u8d8a\u75d2\u8d8a\u6293\uff0c\u8d8a\u6293\u635f\u4f24\u8d8a\u5927\uff0c\u635f\u4f24\u8d8a\u5927\u8d8a\u75d2\u7684\u6076\u6027\u5faa\u73af\u2026\u2026<\/span><\/p>\n


<\/p>\n

\"\u4e00\u62db\u89e3\u51b3\u300c\u4e03\u5e74\u4e4b\u75d2\u300d\uff01\u7279\u5e94\u6027\u76ae\u708e\u836f\u7269<\/p>\n

\u56fe\u7247\u6765\u6e90\uff1a\u7ad9\u9177\u6d77\u6d1b<\/span><\/p>\n


<\/section>\n

\u75d2\u5230\u7761\u4e0d\u7740\uff0c\u751a\u81f3\u7761\u7740\u4e86\u90fd\u4f1a\u6320\u75d2\uff0c\u5728\u7279\u5e94\u6027\u76ae\u708e\u60a3\u8005\u5f53\u4e2d\u8fd8\u771f\u662f\u5e38\u4e8b\u3002\u81f3\u5c11\u6709\u4e09\u5206\u4e4b\u4e00\u7684\u60a3\u8005\uff0c\u4f1a\u53cd\u6620\u7761\u7720\u53d7\u5230\u7619\u75d2\u7684\u5f71\u54cd\uff0c\u8981\u4e48\u7761\u4e0d\u7740\uff0c\u8981\u4e48\u7761\u5f97\u5c11\u9192\u5f97\u9891\u7e41\uff0c\u6709\u4e9b\u7814\u7a76\u7684\u7761\u7720\u53d7\u5f71\u54cd\u60a3\u8005\u6bd4\u4f8b\uff0c\u751a\u81f3\u9ad8\u8fbe 87%<\/span>[4]<\/sup>\uff01<\/span><\/span><\/strong><\/p>\n


<\/section>\n

\u7761\u4e0d\u597d\u4e86\uff0c\u6574\u4e2a\u4eba\u8fd8\u80fd\u597d\u5417\uff1f\u518d\u52a0\u4e0a\u76ae\u80a4\u635f\u4f24\u5bfc\u81f4\u7684\u5916\u89c2\u96be\u582a\uff0c\u5f80\u5f80\u548c\u76ae\u708e\u5171\u60a3\u7684\u54ee\u5598\u3001\u8fc7\u654f\u6027\u9f3b\u708e\u7b49\u75be\u75c5\uff0c<\/span>\u7279\u5e94\u6027\u76ae\u708e\u60a3\u8005\u51fa\u73b0\u6291\u90c1\u3001\u7126\u8651\u75c7\u72b6\u7684\u6bd4\u4f8b\u9ad8\u4e8e\u5e38\u4eba\uff0c\u4e5f\u5c31\u5f88\u5bb9\u6613\u7406\u89e3\u4e86 <\/span>[5]<\/sup>\u3002<\/span><\/span><\/strong>\u8fd9\u4e48\u591a\u91cd\u6298\u78e8\uff0c\u8fd8\u8c08\u4ec0\u4e48\u751f\u6d3b\u8d28\u91cf\u5462\uff1f<\/span><\/p>\n


<\/section>\n

\u6709\u4eba\u80af\u5b9a\u4f1a\u95ee\u4e86\uff0c\u6309\u8fd9\u4e48\u4e00\u8bf4\uff0c\u96be\u9053\u6bcf\u4e2a\u60a3\u8005\u90fd\u662f\u75c5\u60c5\u4e25\u91cd\uff0c\u75db\u4e0d\u6b32\u751f\uff1f<\/span><\/p>\n


<\/section>\n

\u590d\u65e6\u5927\u5b66\u9644\u5c5e\u534e\u5c71\u533b\u9662\u76ae\u80a4\u79d1\u4e3b\u4efb\u533b\u5e08\u674e\u5dcd\u6559\u6388\u8bf4\uff1a\u300c\u7279\u5e94\u6027\u76ae\u708e\u7684\u60a3\u75c5\u7387\u4ee5\u53ca\u75be\u75c5\u8d1f\u62c5\u7684\u4e25\u91cd\u6027\uff0c\u5728\u76ae\u80a4\u7c7b\u75be\u75c5\u4e2d\u6570\u4e00\u6570\u4e8c<\/strong>\uff0c\u800c\u4e14\u60a3\u8005\u5e38\u5408\u5e76\u54ee\u5598\u3001\u8fc7\u654f\u6027\u9f3b\u708e\u7b49\u75be\u75c5\uff0c\u589e\u52a0\u4e86\u60a3\u8005\u7684\u75db\u82e6\u3002\u300d<\/span><\/p>\n


<\/p>\n

\"\u4e00\u62db\u89e3\u51b3\u300c\u4e03\u5e74\u4e4b\u75d2\u300d\uff01\u7279\u5e94\u6027\u76ae\u708e\u836f\u7269<\/section>\n

\u674e\u5dcd\u4e3b\u4efb\u533b\u5e08\u5728\u8fdb\u535a\u4f1a\u73b0\u573a<\/span><\/p>\n


<\/section>\n

\u800c\u4ece\u4e00\u4e9b\u7edf\u8ba1\u6765\u770b\uff0c\u75c7\u72b6\u8fd8\u5728\u8f7b\u5ea6\uff0c\u80fd\u591f\u9760\u4f20\u7edf\u5916\u7528\u6216\u5185\u670d\u836f\u7269\u6cbb\u7597\u7684\u7279\u5e94\u6027\u76ae\u708e\u60a3\u8005\uff0c\u5728\u6574\u4e2a\u60a3\u8005\u7fa4\u4f53\u4e2d\u5927\u6982\u5360\u5230 40-60%<\/span>[6-7]<\/sup>\uff0c\u800c\u5269\u4e0b\u7684\u4e00\u5927\u90e8\u5206\uff0c\u5c31\u662f\u75c5\u60c5\u4e2d\u91cd\u5ea6\u7684\u60a3\u8005\u4e86\u3002<\/strong><\/span><\/span><\/p>\n


<\/section>\n

\u8fd9\u4e9b\u60a3\u8005\u8981\u9762\u5bf9\u7684\uff0c\u662f\u75c5\u7a0b\u6f2b\u957f\u7684\u6298\u78e8\uff0c\u4ee5\u53ca\u4e34\u5e8a\u7f3a\u5c11\u6709\u6548\u7597\u6cd5\u7684\u73b0\u72b6\u3002<\/span><\/strong><\/p>\n


<\/section>\n

\u674e\u5dcd\u6559\u6388\u8868\u793a\uff1a\u300c\u76ee\u524d\u5bf9\u4e8e\u7279\u5e94\u6027\u76ae\u708e\u7684\u6cbb\u7597\u7f3a\u4e4f\u6709\u6548\u4e14\u5b89\u5168\u7684\u624b\u6bb5\uff0c\u5916\u7528\u6fc0\u7d20\u7b49\u5c40\u90e8\u7597\u6cd5\u5bf9\u4e2d\u91cd\u5ea6\u7279\u5e94\u6027\u76ae\u708e\u60a3\u8005\u7597\u6548\u6709\u9650\u4e14\u96be\u4ee5\u957f\u671f\u4f7f\u7528\uff0c\u800c\u514d\u75ab\u6291\u5236\u5242\u6216\u53e3\u670d\u7cd6\u76ae\u8d28\u6fc0\u7d20\u7b49\u7cfb\u7edf\u6027\u6cbb\u7597\u65b9\u5f0f\uff0c\u6709\u53ef\u80fd\u5bfc\u81f4\u4e25\u91cd\u7684\u526f\u4f5c\u7528\u3002\u300d<\/span><\/p>\n


<\/p>\n

\"\u4e00\u62db\u89e3\u51b3\u300c\u4e03\u5e74\u4e4b\u75d2\u300d\uff01\u7279\u5e94\u6027\u76ae\u708e\u836f\u7269<\/section>\n

\u56fe\u7247\u6765\u6e90\uff1a\u7ad9\u9177\u6d77\u6d1b<\/span><\/p>\n


<\/section>\n

\u60a3\u8005\u5bf9\u7279\u5e94\u6027\u76ae\u708e\u7684\u9519\u8bef\u89c2\u5ff5\uff0c\u6bd4\u5982\u5fcc\u53e3\u6cbb\u75c5\u3001\u4e0d\u89c4\u8303\u7528\u836f\u7b49\u7b49\uff0c\u518d\u52a0\u4e0a\u533b\u751f\u8ba4\u77e5\u5ea6\u7684\u6b20\u7f3a\uff0c\u5f80\u5f80\u4f1a\u8ba9\u60a3\u8005\u300c\u96be\u4e0a\u52a0\u96be\u300d\u3002\u600e\u4e48\u529e\uff1f\u5f53\u7136\u4e0d\u80fd\u51c9\u62cc\u3002<\/span><\/p>\n


<\/section>\n

\u5236\u4f4f\u4e24\u5927\u5143\u51f6\uff0c\u53ea\u8981\u4e00\u62db\u5c31\u591f<\/strong><\/strong><\/span><\/p>\n


<\/section>\n
\u8d8a\u96be\u6cbb\u7684\u75be\u75c5\u8d8a\u8981\u94bb\u7814\uff0c\u4e0d\u7136\u600e\u4e48\u80fd\u65a9\u8349\u9664\u6839\u5462\uff1f\u4e5f\u662f\u65f6\u5019\u5bf9\u7279\u5e94\u6027\u76ae\u708e\u7684\u81f4\u75c5\u673a\u5236\u672c\u8eab\uff0c\u6765\u4e2a\u5927\u63ed\u79d8\u5566\u3002<\/span><\/section>\n

<\/section>\n
\u6709\u708e\u75c7\uff0c\u80af\u5b9a\u5c31\u6709\u514d\u75ab\u7684\u53c2\u4e0e\uff0c\u7619\u75d2\u3001\u76ae\u635f\u52a0\u8fc7\u654f\u7684\u4e34\u5e8a\u8868\u73b0\uff0c\u600e\u4e48\u770b\u90fd\u548c\u514d\u75ab\u7cfb\u7edf\u8131\u4e0d\u4e86\u5173\u7cfb\uff0c\u4e0d\u662f\u5417\uff1f\u7279\u5e94\u6027\u76ae\u708e\u7684\u81f4\u75c5\u673a\u5236\uff0c\u81f3\u4eca\u5c1a\u672a\u5b8c\u5168\u660e\u786e\uff0c\u4f46\u6700\u88ab\u8ba4\u53ef\u7684\u5047\u8bf4\uff0c\u8fd8\u662f\u514d\u75ab\u7cfb\u7edf\u7684\u5f02\u5e38\u708e\u75c7\u3002<\/strong><\/span><\/section>\n

<\/section>\n
\u51c6\u786e\u5730\u8bf4\uff0c\u5f02\u5e38\u708e\u75c7\u662f\u6307\u5404\u79cd\u56e0\u7d20\u5bfc\u81f4\u7684\u60a3\u8005\u76ae\u80a4\u5c4f\u969c\u53d7\u635f\uff0c\u60a3\u8005\u63a5\u89e6\u8fc7\u654f\u539f\u540e\uff0c\u88ab\u6fc0\u6d3b\u7684\u7531 2 \u578b\u8f85\u52a9\u6027 T \u7ec6\u80de\u9a71\u52a8\u7684\u5f02\u5e38\u514d\u75ab\u5e94\u7b54\u3002<\/strong>\u57fa\u56e0\u6613\u611f\u6027\u3001\u76ae\u80a4\u5fae\u751f\u7269\u7b49\u8bb8\u591a\u56e0\u7d20\uff0c\u5219\u662f\u5728\u8fd9\u4e2a\u8fc7\u7a0b\u4e2d\u53d1\u6325\u4f5c\u7528<\/span> [1]<\/sup>\u3002<\/span><\/span><\/section>\n
<\/section>\n
\"\u4e00\u62db\u89e3\u51b3\u300c\u4e03\u5e74\u4e4b\u75d2\u300d\uff01\u7279\u5e94\u6027\u76ae\u708e\u836f\u7269<\/section>\n

\u8fd9\u4e2a\u753b\u6cd5\u90fd\u7b97\u7b80\u5316\u7248\u7684\uff0c\u771f\u7684\u2026\u2026<\/span><\/p>\n

\uff08\u56fe\u7247\u6765\u6e90\uff1aJournal of the American Academy of Dermatology\uff09<\/span><\/p>\n


<\/section>\n
\u770b\u8fd9\u5f20\u56fe\u4f1a\u4e0d\u4f1a\u89c9\u5f97\u6709\u4e9b\u773c\u82b1\u7f2d\u4e71\uff1f\u514d\u75ab\u548c\u708e\u75c7\u8fc7\u7a0b\u6709\u65f6\u5019\u662f\u633a\u590d\u6742\uff0c\u4f46\u627e\u51c6\u7a81\u7834\u53e3\u624d\u662f\u5173\u952e\uff0c\u800c\u5728\u7279\u5e94\u6027\u76ae\u708e\u4e0a\u7684\u7a81\u7834\u53e3\uff0c\u5c31\u662f\u53c2\u4e0e\u708e\u75c7\u7684\u4e24\u79cd\u91cd\u8981\u514d\u75ab\u4ecb\u8d28\uff1a<\/strong>\u767d\u4ecb\u7d20-13\uff08IL-13\uff09\u548c\u767d\u4ecb\u7d20-4\uff08IL-4\uff09\u3002<\/strong><\/span><\/section>\n

<\/section>\n
\u4ece\u4f5c\u7528\u4e0a\u8bb2\uff0cIL-13 \u548c IL-4 \u4e00\u4e2a\u662f\u75be\u75c5\u7684\u89e6\u53d1\u5668\uff0c\u4e00\u4e2a\u662f\u75c5\u7406\u4fe1\u53f7\u653e\u5927\u5668<\/strong>\uff0c\u5b83\u4eec\u5728\u88ab 2 \u578b\u8f85\u52a9\u6027 T \u7ec6\u80de\u91ca\u653e\u540e\uff0c\u5c31\u4f1a\u6447\u8eab\u4e00\u53d8\uff0c\u6210\u4e3a\u7279\u5e94\u6027\u76ae\u708e\u7684\u708e\u75c7\u8fc7\u7a0b\u80cc\u540e\uff0c\u63a8\u6ce2\u52a9\u6f9c\u7684\u4e3b\u8981\u63a8\u624b\u3002<\/span><\/section>\n

<\/section>\n
\u523a\u6fc0 B \u7ec6\u80de\u4ea7\u751f IgE\u3001\u62db\u52df\u55dc\u9178\u6027\u7c92\u7ec6\u80de\u589e\u6b96\u3001\u6fc0\u6d3b\u708e\u75c7\u76f8\u5173\u4fe1\u53f7\u901a\u8def\uff0c\u8fd9\u4e00\u7cfb\u5217\u62db\u6570\u88ab IL-13 \u548c IL-4 \u4f7f\u51fa\u6765\uff0c\u663e\u7136\u90fd\u5bf9\u60a3\u8005\u6709\u5bb3\u65e0\u76ca\u3002\u600e\u4e48\u624d\u80fd\u628a\u5b83\u4eec\u5236\u4f4f\u5462\uff1f<\/span><\/section>\n

<\/section>\n
\u5f88\u5de7\u7684\u662f\uff0c\u8fd9\u5bf9\u4e00\u8d77\u81f4\u75c5\u7684\u5144\u5f1f\uff0c\u6cbb\u75c5\u4e5f\u53ef\u4ee5\u4e00\u8d77\u6253\u3002IL-13 \u548c IL-4 \u4f5c\u4e3a\u914d\u4f53\uff0c\u8981\u548c\u76f8\u5e94\u7684\u53d7\u4f53\u7ed3\u5408\u624d\u80fd\u53d1\u6325\u529f\u80fd\uff0c\u800c\u5b83\u4eec\u4fe9\u7ed3\u5408\u7684\u53d7\u4f53\u86cb\u767d\u4e8c\u805a\u4f53\uff0c\u5374\u6709\u5171\u540c\u7684\u90e8\u5206\uff1a<\/strong><\/span>IL-4 \u53d7\u4f53\u03b1\u4e9a\u57fa\uff08IL-4R\u03b1\uff09<\/span>[1]<\/sup>\u3002<\/span><\/span><\/strong><\/section>\n

<\/section>\n
\"\u4e00\u62db\u89e3\u51b3\u300c\u4e03\u5e74\u4e4b\u75d2\u300d\uff01\u7279\u5e94\u6027\u76ae\u708e\u836f\u7269<\/section>\n
IL-4 \u548c IL-13 \u90fd\u53ef\u4ee5\u7ed3\u5408\u4e24\u79cd\u914d\u4f53\uff0c\u5176\u4e2d\u6709\u4e00\u79cd\u662f\u5171\u7528\uff0c\u800c IL-4R\u03b1\u53c2\u4e0e\u4e86\u5168\u90e8\u4e09\u79cd\u914d\u4f53\u4e2d\u7684\u4e24\u79cd<\/span><\/section>\n
\uff08\u56fe\u7247\u6765\u6e90\uff1aExpert Reviews of Clinical Immunology\uff09<\/span><\/section>\n

<\/section>\n
\u60f3\u529e\u6cd5\u628a\u8fd9\u4e2a\u4e9a\u57fa\u63d0\u524d\u5360\u4f4f\uff0c\u4e0d\u8ba9 IL-13 \u548c IL-4 \u6765\u5360\uff0c\u4e0d\u5c31\u80fd\u591f\u5236\u4f4f\u5b83\u4eec\u4fe9\uff0c\u4ece\u800c\u5728\u7f13\u89e3\u708e\u75c7\u65b9\u9762\u5360\u636e\u4e0a\u98ce\uff0c\u5b9e\u73b0\u5bf9\u7279\u5e94\u6027\u76ae\u708e\u75c5\u60c5\u7684\u63a7\u5236\u4e86\uff1f\u800c\u8fd9\u79cd\u804c\u8d23\uff0c\u4ea4\u7ed9\u5355\u514b\u9686\u6297\u4f53\u80af\u5b9a\u662f\u6700\u5408\u9002\u7684\u3002<\/span><\/section>\n

<\/section>\n
\u4e3a\u8fd9\u9879\u4f7f\u547d\u800c\u751f\u7684\u5355\u514b\u9686\u6297\u4f53 Dupilumab\uff0c\u5c31\u6210\u4e3a\u4e86\u7b2c\u4e00\u79cd\u83b7\u6279\u7528\u4e8e\u7279\u5e94\u6027\u76ae\u708e\u6cbb\u7597\u7684\u751f\u7269\u5236\u5242<\/strong>\uff0c\u6b64\u540e\u5b83\u7684\u4f7f\u7528\u8fd8\u6269\u5c55\u5230\u4e86\u54ee\u5598\u3001\u6162\u6027\u9f3b\u7aa6\u708e\u7b49\u540c\u6837\u6709 IL-13 \u548c IL-4 \u53c2\u4e0e\u7684\u75be\u75c5\u5f53\u4e2d\u3002<\/span><\/section>\n

<\/section>\n
\u90a3\u4e48\u5728\u6700\u521d\u7684\u6218\u573a\u4e0a\uff0cDupilumab \u4ea4\u51fa\u7684\u8868\u73b0\u5230\u5e95\u6709\u591a\u597d\uff0c\u624d\u80fd\u8ba9\u6574\u4e2a\u533b\u5b66\u5708\u522e\u76ee\u76f8\u770b\u5462\uff1f<\/span><\/section>\n
<\/section>\n

<\/section>\n

\u540d\u526f\u5176\u5b9e\u7684\u91cd\u78c5\u70b8\u5f39<\/span><\/strong><\/span><\/p>\n


<\/p>\n

2016 \u5e74 10 \u6708\uff0cDupilumab \u5355\u836f\u6cbb\u7597\u7279\u5e94\u6027\u76ae\u708e\u7684 SOLO 1\/2 \u4e24\u9879 III \u671f\u4e34\u5e8a\u8bd5\u9a8c\u7ed3\u679c\uff0c\u516c\u5e03\u5728\u4e86\u300a\u65b0\u82f1\u683c\u5170\u533b\u5b66\u6742\u5fd7\u300b\u4e0a <\/span>[8]<\/sup>\u3002<\/span><\/span>\u7528\u4e00\u4f4d\u4e13\u5bb6\u63a5\u53d7\u300a\u7ebd\u7ea6\u65f6\u62a5\u300b\u91c7\u8bbf\u65f6\u7684\u8bdd\u8bf4\uff0c<\/span>\u8fd9\u7ed3\u679c\u8ba9\u300c\u7279\u5e94\u6027\u76ae\u708e\u7684\u6cbb\u7597\uff0c\u8fdb\u5165\u4e86\u5168\u65b0\u7684\u65f6\u4ee3\u300d<\/span>[9]<\/sup>\u3002<\/span><\/span><\/strong><\/span><\/p>\n


<\/p>\n

\u5176\u5b9e\u8fd9\u8bdd\u8bf4\u5f97\u6beb\u4e0d\u5938\u5f20\uff0c\u4f46\u4e0d\u89e3\u8bfb\u4e00\u4e0b\u8bd5\u9a8c\uff0c\u8fd8\u771f\u770b\u4e0d\u51fa Dupilumab \u7684\u4ef7\u503c\u3002\u8fd9\u4e24\u9879 III \u671f\u4e34\u5e8a\u8bd5\u9a8c\u5171\u5165\u7ec4\u4e86\u8fd1 1400 \u540d\u75c5\u60c5\u8fbe\u5230\u4e2d\u91cd\u5ea6\uff0c\u4f20\u7edf\u5c40\u90e8\u7597\u6cd5\u63a7\u5236\u4e0d\u4f73\u7684\u60a3\u8005\uff0c\u8fdb\u884c\u4e3a\u671f 16 \u5468\u7684\u8bd5\u9a8c\u3002<\/span><\/p>\n


<\/p>\n

\u8861\u91cf\u7597\u6548\u7684\u6307\u6807\u5219\u662f\u7814\u7a76\u8005\u603b\u4f53\u8bc4\u5206\uff08IGA\uff09\uff0c\u5b83\u662f\u6307\u4e34\u5e8a\u533b\u751f\u5bf9\u60a3\u8005\u5168\u8eab\u76ae\u708e\u75c7\u72b6\u7684\u8bc4\u5b9a\uff0c\u5206\u6570\u8d8a\u4f4e\u8d8a\u597d\uff0c0 \u5206\u5c31\u662f\u76ae\u80a4\u635f\u4f24\u5f7b\u5e95\u6d88\u5931\u3002\u8bd5\u9a8c\u7684\u4e3b\u8981\u7ec8\u70b9\uff0c\u8981\u6c42\u60a3\u8005\u7684 IGA \u8bc4\u5206\u8fbe\u5230 0 \u6216 1\uff081 \u5206\u4ee3\u8868\u51e0\u4e4e\u65e0\u76ae\u635f\uff09\uff0c\u4e14\u6bd4\u8bd5\u9a8c\u5f00\u59cb\u65f6\u964d\u81f3\u5c11 2 \u5206\u3002<\/span><\/p>\n


<\/p>\n

\u63a5\u53d7 Dupilumab \u5355\u836f\u6bcf\u4e24\u5468\u4e00\u6b21\u6cbb\u7597\u7684\u60a3\u8005\uff0c\u8fbe\u5230\u4e3b\u8981\u7ec8\u70b9\u7684\u60a3\u8005\u6bd4\u4f8b\u5728\u4e24\u9879\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u662f 36-38%\uff0c\u660e\u663e\u9ad8\u4e8e\u5b89\u6170\u5242\u7ec4 8-10% \u7684\u6c34\u5e73\uff01<\/span><\/strong><\/p>\n


<\/p>\n

\u5728\u8861\u91cf\u7597\u6548\u7684\u6b21\u8981\u7ec8\u70b9\uff0c\u5c24\u5176\u662f\u6e7f\u75b9\u9762\u79ef\u53ca\u4e25\u91cd\u7a0b\u5ea6\u6307\u6570\uff08EASI\uff09\u6539\u5584\u8d85\u8fc7 75%\uff08EASI-75\uff09\u7684\u8bc4\u5b9a\u4e0a\uff0cDupilumab \u6cbb\u7597\u8ba9\u8d85\u8fc7 50% \u7684\u60a3\u8005\u8fbe\u6807\uff0c\u8db3\u8db3\u662f\u5355\u7eaf\u5b89\u6170\u5242\u7684\u4e09\u500d\uff01<\/span>[9]<\/sup><\/span><\/p>\n


<\/p>\n

\"\u4e00\u62db\u89e3\u51b3\u300c\u4e03\u5e74\u4e4b\u75d2\u300d\uff01\u7279\u5e94\u6027\u76ae\u708e\u836f\u7269<\/section>\n

Dupilumab \u5728 IGA \u548c EASI-75 \u4e24\u9879\u7ec8\u70b9\u4e0a\u5927\u80dc\uff0cSCORAD \u7b49\u5176\u5b83\u6b21\u8981\u7ec8\u70b9\u4e0a\u4e5f\u662f\u5360\u5c3d\u4e0a\u98ce<\/span><\/p>\n

\uff08\u56fe\u7247\u6765\u6e90\uff1a\u53c2\u8003\u6587\u732e 8\uff09<\/span><\/p>\n


<\/p>\n

\u51fa\u8272\u7684\u8868\u73b0\uff0c\u8ba9 Dupilumab \u5728 2017 \u5e74\u88ab FDA \u6279\u51c6\u4e0a\u5e02\uff0c\u800c\u540c\u5e74\u767b\u4e0a\u300a\u67f3\u53f6\u5200\u300b\u7684 CHRONOS \u8bd5\u9a8c\u4e2d\uff0cDupilumab \u4e0e\u4f20\u7edf\u7684\u7cd6\u76ae\u8d28\u6fc0\u7d20\u7597\u6cd5\u8054\u5408\uff0c\u5728 EASI-75 \u6307\u6807\u65b9\u9762\u66f4\u8fdb\u4e00\u6b65\uff0c\u60a3\u8005\u8fbe\u6807\u6bd4\u4f8b\u8fbe\u5230\u4e86 69%\uff0c\u662f\u5b89\u6170\u5242\u7ec4\u7684\u4e09\u500d <\/span>[10]<\/sup>\u3002<\/span><\/span><\/p>\n


<\/p>\n

\u53d7\u76ca\u4e8e\u76f8\u5173\u653f\u7b56\u7684\u6539\u8fdb\uff0c2019 \u5e74 2 \u6708\uff0c\u6d77\u5357\u535a\u9ccc\u8d85\u7ea7\u533b\u9662\u7528 Dupilumab \u6cbb\u7597\u4e86\u7b2c\u4e00\u540d\u7279\u5e94\u6027\u76ae\u708e\u60a3\u8005\u3002<\/span><\/strong><\/p>\n


<\/p>\n

\u53c2\u4e0e\u8fd9\u300c\u7b2c\u4e00\u9488\u300d\u7684\u590d\u65e6\u5927\u5b66\u76ae\u80a4\u75c5\u7814\u7a76\u6240\u6240\u957f\u5f20\u5b66\u519b\u6559\u6388\u8868\u793a\uff1a\u300c\u9776\u5411\u751f\u7269\u5236\u5242\u4e3a\u4e2d\u91cd\u5ea6\u76ae\u708e\u60a3\u8005\u63d0\u4f9b\u4e86\u4e00\u79cd\u521b\u65b0\u3001\u9ad8\u6548\uff0c\u5b89\u5168\u6027\u786e\u5207\u7684\u6cbb\u7597\u65b0\u9009\u62e9\uff0c\u5df2\u7ecf\u63a5\u53d7\u6cbb\u7597\u7684\u60a3\u8005\u76ae\u635f\u9762\u79ef\u548c\u7619\u75d2\u7a0b\u5ea6\u90fd\u5f97\u5230\u4e86\u6539\u5584\uff0c\u751f\u6d3b\u8d28\u91cf\u4e5f\u5f97\u5230\u663e\u8457\u63d0\u9ad8\u3002<\/strong>\u300d<\/strong><\/span><\/p>\n


<\/p>\n

\"\u4e00\u62db\u89e3\u51b3\u300c\u4e03\u5e74\u4e4b\u75d2\u300d\uff01\u7279\u5e94\u6027\u76ae\u708e\u836f\u7269<\/section>\n

\u5f20\u5b66\u519b\u6559\u6388\u5728\u8fdb\u535a\u4f1a\u73b0\u573a<\/span><\/p>\n


<\/p>\n

Dupilumab \u4e5f\u6b63\u5728\u5f00\u5c55\u4e13\u95e8\u9488\u5bf9\u4e2d\u56fd\u60a3\u8005\u7684\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u4ece\u535a\u9ccc\u533b\u9662\u7684\u7b2c\u4e00\u9488\u5230\u5168\u9762\u8fdb\u519b\u4e2d\u56fd\uff0c\u771f\u662f\u76f8\u5f53\u8fc5\u901f\u4e86\u3002\u6446\u8131\u6389\u96be\u5fcd\u4e4b\u75d2\uff0c\u65e0\u7591\u662f\u5fc3\u5934\u843d\u4e0b\u4e00\u5757\u5de8\u77f3\uff0c\u4e0d\u662f\u5417\uff1f<\/span><\/p>\n


<\/p>\n


<\/p>\n

\u672c\u6587\u9996\u53d1\u4e8e\u5fae\u4fe1\u516c\u4f17\u53f7\u5947\u70b9\u7f51\uff08ID\uff1ageekheal_com\uff09\u6388\u6743\u8f6c\u8f7d\u53d1\u5e03<\/span><\/p>\n

\u8d23\u7f16\uff1aCici<\/span><\/p>\n


<\/p>\n

\u6b22\u8fce\u5411\u62a5\u6599\uff01<\/span><\/em><\/span>\u8bf7\u52a0\u5fae\u4fe1\uff1adxylzzb<\/span><\/em><\/p>\n

\"\u4e00\u62db\u89e3\u51b3\u300c\u4e03\u5e74\u4e4b\u75d2\u300d\uff01\u7279\u5e94\u6027\u76ae\u708e\u836f\u7269<\/section>\n


<\/p>\n

\u9898\u56fe\u6765\u6e90\uff1a\u7ad9\u9177\u6d77\u6d1b
<\/span><\/p>\n

\u53c2\u8003\u6587\u732e\uff1a<\/span><\/p>\n

1.<\/span>Weidinger S, Beck L A, Bieber T, et al. Atopic dermatitis[J]. Nature Reviews Disease Primers, 2018, 4(1): 1.<\/span><\/p>\n

2.<\/span>Guo Y, Li P, Tang J, et al. Prevalence of atopic dermatitis in chinese children aged 1\u20137 ys[J]. Scientific Reports, 2016, 6: 29751.<\/span><\/p>\n

3.<\/span>Wang X, Li L F, Zhao D, et al. Prevalence and clinical features of atopic dermatitis in China[J]. BioMed Research International, 2016: 2568301.<\/span><\/p>\n

4.Jeon C, Yan D, Nakamura M, et al. Frequency and management of sleep disturbance in adults with atopic dermatitis: a systematic review[J]. Dermatology and Therapy, 2017, 7(3): 349-364.<\/span>
<\/p>\n

5.<\/span>Silverberg J I, Gelfand J M, Margolis D J, et al. Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults[J]. British Journal of Dermatology, 2019, 181(3): 554-565.<\/span><\/p>\n

6.<\/span>Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: Results from an international survey[J]. Allergy, 2018, 73(6): 1284-1293.<\/span><\/p>\n

7.<\/span>Fuxench Z C C, Block J K, Boguniewicz M, et al. Atopic Dermatitis in America Study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population[J]. Journal of Investigative Dermatology, 2019, 139(3): 583-590.<\/span><\/p>\n

8.<\/span>Simpson E L, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis[J]. New England Journal of Medicine, 2016, 375(24): 2335-2348.<\/span><\/p>\n

9.<\/span>https:\/\/www.nytimes.com\/2016\/10\/01\/health\/severe-eczema-atopic-dermatitis-drug.html<\/span><\/p>\n

10.<\/span>Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial[J]. The Lancet, 2017, 389(10086): 2287-2303.<\/span><\/p>\n


<\/p>\n<\/section>\n<\/section>\n


<\/p>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"

\u670b\u53cb\uff0c\u4f60\u542c\u8bf4\u8fc7 AD \u5417\uff1f \u4e0d\u4e0d\uff0c\u4e0d\u662f\u8bf4\u963f\u5c14\u8328\u6d77\u9ed8\u75c5\uff0c\u4f46\u8fd9\u4e2a AD\uff0c\u8bba\u53ef\u6015\u7a0b\u5ea6\u5374\u6beb\u4e0d\u900a\u8272\uff0c\u5b83\u53eb\u7279\u5e94\u6027\u76ae\u708e\uff08At […]<\/p>\n","protected":false},"author":1,"featured_media":128004,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[2],"tags":[],"_links":{"self":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/128003"}],"collection":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/comments?post=128003"}],"version-history":[{"count":1,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/128003\/revisions"}],"predecessor-version":[{"id":128014,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/128003\/revisions\/128014"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media\/128004"}],"wp:attachment":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media?parent=128003"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/categories?post=128003"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/tags?post=128003"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}